Document is current
Any future updates will be listed below
-
Authors
Adeel, Komal
Fergusson, Nathan J.
Shorr, Risa
Atkins, Harold
Hay, Kevin A. https://orcid.org/0000-0002-9398-2677
-
Funding
Funding for this research was provided by:
BioCanRx (Ref #FY20/ES15, Ref # FY20/SS10)
- License Information
-
More Information
Article History
Received: 21 August 2020
Accepted: 11 January 2021
First Online: 21 January 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: KAH has received honorarium for speaking engagements from Jazz Pharmaceuticals and served on advisory boards for Kite/Gilead and Celgene/BMS. KAH is principal investigator on a BioCanRx grant (Ref #FY20/ES15) “Enabling a Phase I/II multicenter clinical trial of a novel single domain (sd)CD22 specific camelid chimeric antigen receptor (CAR) T-cell therapy”. HA is a co-investigator on an Ontario Institute for Cancer Research grant “Using real-world data and iterative economic evaluation to prioritize resource allocation for care and research in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia”. HA is also a member of a Council of Canadian Academies expert panel examining the legal, ethical, social, and policy challenges surrounding gene and engineered cell therapies.
